Feliza Mirasol

A slew of late-stage clinical trials is expected to push new regenerative medicines onto the market in the next few years.

Improvement in viral vector yield has become integral to new cell and gene therapy product development.

Single-use systems hold key benefits for biomanufacturers, despite certain limitations.

Biologic drug development requires relevant bioassays to measure and help predict cellular response.

Deeper biological understanding and technology innovations have improved the fate of ADC development.

Learning from early market failures, the biopharma industry has worked to improve the fate of antibody drug conjugates.

Using a predictive modeling approach can help tighten up operator control over bioprocessing, which in turn can increase bioreactor output.

The industry revisits the pros and cons of microbial fermentation at scale for biotherapeutics.

A simplified downstream process can save time and costs but requires enabling technologies.

The growth of the biopharmaceuticals market is feeding back into economies and, in part, is driving the boom in life sciences and biotech ecosystems.